FrancophonIA/ELRC3.0 huggingface dataset:
English: Tacrolimus, the active substance in Envarsus, is an immunosuppressive medicine.
Slovenian: Takrolimus, zdravilna učinkovina v zdravilu Envarsus, je zdravilo za zaviranje imunske odzivnosti.
English: How is Envarsus used?
Slovenian: Kako se zdravilo Envarsus uporablja?
English: For the full list of all side effects reported with Envarsus see the package leaflet
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Envarsus, glejte navodilo za uporabo.
English: How does Envarsus work?
Slovenian: Kako zdravilo Envarsus deluje?
English: What measures are being taken to ensure the safe and effective use of Adynovi?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Adynovi?
English: The full EPAR for Adynovi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Adynovi je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Adynovi
Slovenian: Druge informacije o zdravilu Adynovi
English: This is a summary of the European public assessment report (EPAR) for Adynovi.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Adynovi.
English: Around 83% of bleeding episodes resolved with one injection.
Slovenian: Približno 83 % epizod krvavitev so obvladali z eno injekcijo.
English: The European Medicines Agency decided that Adynovi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Adynovi večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
English: Since this could potentially cause problems especially in children below 12 years of age, Adynovi is only approved for use in adults and children from 12 years of age.
Slovenian: Ker lahko to povzroči težave, zlasti pri otrocih, mlajših od 12 let, je zdravilo Adynovi odobreno le za uporabo pri odraslih in otrocih, starejših od12 let.
English: During this period, around 38% of patients (25 out of 66) had no bleeding episodes, and none of the patients developed antibodies against Adynovi, which can cause the medicine to stop working.
Slovenian: V tem obdobju približno 38 % (25 od 66) bolnikov ni imelo nobene epizode krvavitve, pri nobenem od bolnikov pa se niso razvila protitelesa proti zdravilu Adynovi, zaradi katerih lahko zdravilo preneha delovati.
English: Patients or their carers may be able to inject Adynovi themselves at home once they have been trained appropriately.
Slovenian: Bolniki ali njihovi skrbniki lahko po ustreznem usposabljanju zdravilo Adynovi injicirajo sami doma.
English: For the full list of all side effects see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov glejte navodilo za uporabo.
English: The dose and frequency of treatment depend on whether it is used to treat or prevent bleeding, as well as on the seriousness of the haemophilia, the extent and location of the bleeding and the patient's condition and bodyweight.
Slovenian: Odmerek in pogostnost injiciranja sta odvisna od tega, ali se zdravilo uporablja za zdravljenje ali preprečevanje krvavitev, ter od resnosti hemofilije, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
English: Adynovi rurioctocog alfa pegol
Slovenian: Adynovi rurioktokog alfa pegol
English: What benefits of Adynovi have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Adynovi izkazalo v študijah?
English: What is Adynovi and what is it used for?
Slovenian: Kaj je zdravilo Adynovi in za kaj se uporablja?
English: Hypersensitivity (allergic) reactions are uncommon with Adynovi (affecting up to 1 in 100 people) and may include swelling, burning and stinging at the injection site, chills, flushing, itchy rash, headache, hives, low blood pressure, lethargy, nausea and vomiting, restlessness, a rapid heartbeat, tightness of the chest and wheezing.
Slovenian: Občasne preobčutljivostne (alergijske) reakcije pri uporabi zdravila Adynovi (ki se lahko pojavijo pri največ 1 bolniku od 100) lahko vključujejo oteklost, pekoč občutek in zbadanje na mestu injiciranja, mrzlico, vročinske oblive, srbeč izpuščaj, glavobol, koprivnico, nizek krvni tlak, letargijo, navzejo in bruhanje, nemir, hiter srčni utrip, tiščanje v prsnem košu in piskanje v pljučih.
English: In a study involving 138 adults and adolescents aged 12 years or above, 120 patients given Adynovi as a twice-weekly preventive treatment had, on average, around 4 bleeding episodes a year, and 17 patients given Adynovi for treating bleedings ‘on demand' had around 43 bleeding episodes a year.
Slovenian: V študiji, ki je vključevala 138 odraslih in mladostnikov, starejših od 12 let, je 120 bolnikov, ki so prejemali zdravilo Adynovi dvakrat tedensko kot preventivno zdravljenje, imelo v povprečju približno štiri epizode krvavitev na leto, 17 bolnikov, ki so prejemali zdravilo Adynovi za zdravljenje krvavitev po potrebi, pa je imelo približno 43 epizod krvavitev na leto.
English: Why is Adynovi approved?
Slovenian: Zakaj je bilo zdravilo Adynovi odobreno?
English: It can be used in adults and children from 12 years of age.
Slovenian: Zdravilo Adynovi se lahko uporablja pri odraslih in otrocih, starejših od 12 let.
English: Around 96% of bleeding episodes resolved with one or two injections of Adynovi.
Slovenian: Približno 96 % epizod krvavitev so obvladali z eno ali dvema injekcijama zdravila Adynovi.
English: It is not intended to provide practical advice on how to use Adynovi.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Adynovi have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Adynovi upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: The company that markets Adynovi will conduct a study to investigate the potential effects of PEG accumulation in the choroid plexus of the brain and other organs.
Slovenian: Družba, ki trži zdravilo Adynovi, bo izvedla študijo za proučitev morebitnega učinka kopičenja PEG v horoidnem pletežu možganov in drugih organih.
English: What are the risks associated with Adynovi?
Slovenian: Kakšna tveganja so povezana z zdravilom Adynovi?
English: In the second study in 66 children aged below 12 years, all patients were given Adynovi as a twiceweekly preventive treatment for around 6 months.
Slovenian: V drugi študiji, ki je vključevala 66 otrok, mlajših od 12 let, so zdravilo Adynovi kot preventivno zdravljenje dvakrat tedensko približno šest mesecev prejemali vsi bolniki.
English: The active substance in Adynovi, rurioctocog alfa pegol, works in the body in the same way as human factor VIII.
Slovenian: Zdravilna učinkovina v zdravilu Adynovi, rurioktokog alfa pegol, deluje v telesu enako kot humani faktor VIII.
English: Adynovi must not be used in patients who are hypersensitive (allergic) to rurioctocog alfa pegol or the related substance octocog alfa or to any of the other ingredients of the medicine, nor in those with known allergy to mouse or hamster proteins.
Slovenian: Zdravilo Adynovi se ne sme uporabljati pri bolnikih, ki so preobčutljivi za (alergični na) rurioktokog alfa pegol, na sorodno snov oktokog alfa ali na katero koli drugo sestavino zdravila, in pri bolnikih z znano alergijo na beljakovine miši ali hrčka.
English: For more information about treatment with Adynovi, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Adynovi preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Following treatment with factor VIII products, including Adynovi, some patients may develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.
Slovenian: Po zdravljenju z zdravili s faktorjem VIII, vključno z zdravilom Adynovi, se lahko pri nekaterih bolnikih pojavijo zaviralci (protitelesa) faktorja VIII, ki izničijo delovanje zdravila in tako povzročijo izgubo nadzora nad krvavitvijo.
English: Adynovi is available as a powder and solvent that are mixed together to make a solution for injection into a vein.
Slovenian: Zdravilo Adynovi je na voljo v obliki praška in vehikla, ki se zmešata za pripravo raztopine za injiciranje v veno.
English: Adynovi can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Slovenian: Predpisovanje in izdaja zdravila Adynovi je le na recept, zdravljenje z njim pa mora biti pod nadzorom zdravnika z izkušnjami pri zdravljenju hemofilije.
English: For practical information about using Adynovi, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Adynovi naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Adynovi has been shown in two main studies to be effective at preventing and treating bleeding episodes in patients with severe haemophilia who were previously treated with other factor VIII products.
Slovenian: V dveh glavnih študijah se je zdravilo Adynovi izkazalo za učinkovito pri preprečevanju in zdravljenju epizod krvavitev pri bolnikih s hudo hemofilijo, ki so bili prej zdravljeni z drugimi zdravili s faktorjem VIII.
English: In addition, when bleeding did occur, Adynovi was rated excellent or good at treating around 96% of bleeding episodes.
Slovenian: Poleg tega je bilo ob pojavu krvavitve zdravljenje z zdravilom Adynovi ocenjeno kot odlično ali dobro pri približno 96 % epizod krvavitev.
English: However, part of the active substance in Adynovi (called PEG) may accumulate in the body, including in a structure in the brain called the choroid plexus, following long-term treatment.
Slovenian: Vendar pa se lahko del zdravilne učinkovine zdravila Adynovi (imenovan PEG) po dolgotrajnem zdravljenju kopiči v telesu, tudi v strukturi v možganih, imenovani horoidni pletež.
English: Adynovi is a medicine used to treat and prevent bleeding in patients with haemophilia A, an inherited bleeding disorder caused by lack of a clotting protein called factor VIII.
Slovenian: Zdravilo Adynovi se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A, tj. prirojeno motnjo strjevanja krvi zaradi pomanjkanja koagulacijske beljakovine, imenovane faktor VIII.
English: When bleeding occurred, Adynovi was rated excellent or good at treating around 90% of episodes.
Slovenian: Poleg tega je bilo ob pojavu krvavitve zdravljenje z zdravilom Adynovi ocenjeno kot odlično ali dobro pri približno 90 % epizod.
English: Studies show that Adynovi is effective at preventing and treating bleeding episodes in patients with haemophilia A and its safety is comparable to that of other factor VIII products.
Slovenian: Študije so pokazale, da zdravilo Adynovi učinkovito preprečuje in zdravi epizode krvavitev pri bolnikih s hemofilijo A ter da je varnost zdravila primerljiva z varnostjo drugih zdravil s faktorjem VIII.
English: How is Adynovi used?
Slovenian: Kako se zdravilo Adynovi uporablja?
English: How does Adynovi work?
Slovenian: Kako zdravilo Adynovi deluje?
English: Adynovi contains the active substance rurioctocog alfa pegol.
Slovenian: Zdravilo Adynovi vsebuje zdravilno učinkovino rurioktokog alfa pegol.
English: Wash hands after use.
Slovenian: Umijte si roke po uporabi.
English: Advice for Veterinarian:
Slovenian: Nasvet za veterinarja:
English: Avoid contact with eyes.
Slovenian: Izogibajte se stiku zdravila z očmi.
English: EU/2/07/071/002 (50ml) EU/2/07/071/003 (150ml)
Slovenian: EU/2/07/071/001 (20 ml) EU/2/07/071/002 (50 ml) EU/2/07/071/003 (150 ml)
English: This is the starting dose for a 5 kg dog.
Slovenian: To je začetni odmerek za 5 kg težkega psa.
English: Use in dogs intended for breeding should be subject to a risk-benefit analysis (see section 4.7).
Slovenian: Uporaba pri psih, namenjenih za vzrejo, naj bo predmet ocene tveganja - koristi (glejte poglavje 4.7).
English: Systemic exposure was 1.5 times higher in fed dogs.
Slovenian: Sistemska izpostavljenost je bila pri nahranjenih psih 1,5-krat večja.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes)
Slovenian: 4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno)
English: In a 14-day repeated dose study, AUC increased 3-fold from Day 1to Day 14.
Slovenian: V 14-dnevni študiji s ponavljajočim se odmerkom se je AUC na 14. dan povečala 3-krat v primerjavi s prvim dnem.
English: Mean oral bioavailability values were approximately 24% - 41% for fed dogs and 22% in fasted dogs.
Slovenian: Srednja biološka uporabnost je bila 24 % - 41 % za nahranjene pse in 22 % na tešče.
English: Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Slovenian: Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).
English: Interactions with other drug types have not been specifically investigated.
Slovenian: Interakcije z drugimi zdravili niso bile podrobno preučene.
English: In a radiolabeled metabolism study, the primary route of excretion was via the faeces with minimal excretion via urine (<1%).
Slovenian: V študiji presnove z radioizotopom je bila primarna pot izločanja z blatom in minimalna ekskrecija z urinom (<1 %).
English: Do not use in dogs in which overweight or obesity is caused by a concomitant systemic disease such as hypothyroidism or hyperadrenocorticism.
Slovenian: Ne uporabite zdravila pri psih, pri katerih je prekomerna telesna masa ali debelost posledica sočasne sistemske bolezni kot so hipotireoidizem ali hiperadrenokorticizem.
English: ATCvet code: QA08AB91
Slovenian: Oznaka ATC vet: QA08AB91.
English: Ingestion can be harmful to children and pregnant women.
Slovenian: Zaužitje je lahko škodljivo za otroke in noseče ženske.
English: The veterinarian will advise you when dose adjustments become necessary.
Slovenian: Veterinar bo svetoval, kdaj bo potrebno prilagoditi odmerek.
English: If you notice any serious effects or other effects not mentioned in this package leaflet, please inform
Slovenian: Če opazite kakršne koli resne stranske učinke ali druge učinke, ki niso omenjeni v teh navodilih za
English: The efficacy of dirlotapide has been demonstrated with various types of diets, representing the whole range of fat contents available in commercial diets.
Slovenian: Učinkovitost dirlotapida je bila prikazana na različnih tipih diet, ki so zajele ves spekter komercialnih diet, ki so na voljo na trgu.
English: The effect is mainly mediated indirectly due to reduced feed intake during therapy.
Slovenian: Učinek je v glavnem posreden zaradi zmanjšanega vnosa hrane med zdravljenjem.
English: Slentrol 5 mg/ml oral solution for dogs
Slovenian: Slentrol 5 mg/ml peroralna raztopina za pse
English: Do not use this veterinary medicinal product after the expiry date which is stated on the bottle.
Slovenian: Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na steklenički.
English: Date of first authorisation: 13/04/2007
Slovenian: Datum podaljšanja dovoljenja za promet: 10/04/2012
English: Shelf life of the veterinary medicinal product as packaged for sale: 5 years
Slovenian: Rok uporabnosti zdravila v pakiranju za prodajo: 5 leta
English: Dirlotapide is a potent selective inhibitor of the Microsomal Triglyceride transfer Protein (MTP).
Slovenian: Dirlotapid je močan, selektiven inhibitor mikrosomalnega proteina za prenos trigliceridov (MTP).
English: To be used as part of an overall weight management programme which also includes appropriate dietary changes and exercise
Slovenian: Uporabiti kot del celotnega programa nadziranja telesne mase, ki vključuje tudi primerne spremembe v prehrani in
English: Some dogs (less than 10%) experienced repeated vomiting (i.e. more than once every 20 days on average).
Slovenian: Nekateri psi (manj kot 10 %) so bruhali večkrat (to je v povprečju več kot enkrat vsakih 20 dni).
English: Additionally, dirlotapide was highly protein bound (>99%) in dog plasma.
Slovenian: Dirlotapid se močno veže na proteine v plazmi (99 %) pri psu.
English: These signs typically started during the first month of treatment (about 30% of dogs showed at least one vomiting event and up to 12% showed any of the other signs) and decreased continuously during the course of treatment.
Slovenian: Našteti znaki so se tipično pojavili v prvem mesecu zdravljenja (okoli 30 % psov je imelo vsaj eno epizodo z bruhanjem, do 12 % psov je kazalo ostale znake) in so se postopoma zmanjševali med nadaljevanjem zdravljenja.
English: Your veterinary surgeon will identify a target weight and explain how Slentrol should be used as part of an overall weight management programme which also includes appropriate dietary changes and exercise practice.
Slovenian: Lečeči veterinar bo določil ciljno maso in razložil, kako se Slentrol uporablja kot del vodenja celotnega programa znižanja telesne mase, ki bo vključeval tudi primerne spremembe prehrane in gibalne aktivnosti.
English: Store in the original container in order to protect from light.
Slovenian: Shranjujte v originalni vsebniku da se zaščiti pred svetlobo.
English: Oral dosing devices used for measuring the dose may be cleaned with water but must be dried before re-use.
Slovenian: Peroralno napravo za odmerjanje se lahko čisti z vodo, vendar jo morate pred nadaljnjo uporabo osušiti.
English: Clinical and pharmacodynamic data strongly suggest that the efficacy of dirlotapide results from a primary local action in the gut after oral administration.
Slovenian: Klinični in farmakodinamični podatki močno kažejo na to, da je učinkovitost delovanja dirlotapida v črevesju rezultat primarne lokalne aktivnosti po peroralnem dajanju.
English: EXP {month/year} Once opened, use within 3 months
Slovenian: EXP {mesec/leto} Načeto/odprto zdravilo uporabite v treh mesecih
English: Systemic blood levels of dirlotapide are not well correlated with efficacy in the dog.
Slovenian: Sistemske vrednosti dirlotapida v krvi niso v korelaciji z učinkom pri psih.
English: AUC and Cmax increased with increasing dose but not in a dose-proportional manner.
Slovenian: Površina pod krivuljo (area under the curve - AUC) in Cmax sta se povečala s povečanjem odmerka toda ne proporcionalno s povečanjem odmerka.
English: Pharmacotherapeutic group: Peripherally acting antiobesity products.
Slovenian: FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: periferno delujoče zdravilo proti debelosti.
English: As a consequence of reducing intestinal fat absorption, dirlotapide reduces food intake in dogs in a dose-dependent manner.
Slovenian: Kot posledica zmanjšanja črevesne resorpcije maščob, dirlotapid zmanjša jemanje hrane pri psih, kar je odvisno od odmerka.
English: The first time a conditional increase is required, the dose should be increased by 100%, (doubled).
Slovenian: Pri prvem pogojnem povečanju odmerka, se odmerek poveča za 100 % (podvoji).
English: Special precautions to be taken by the person administering the veterinary medicinal product to dogs: The veterinary medicinal product does not mix with water.
Slovenian: Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo: Zdravilo se ne meša z vodo.
English: This food inhibitory effect of dirlotapide results from a primary local effect on the gastrointestinal tract following oral administration and is not a result of systemic exposure.
Slovenian: Inhibitorni dirlotapidov efekt na hrano izhaja iz primarnega lokalnega učinka na gastrointestinalni trakt po peroralnem dajanju in ni rezultat sistemskega delovanja.
English: Where the veterinary medicinal product has been administered on food, discard unconsumed food immediately to avoid unintentional ingestion by other animals or persons in the household.
Slovenian: Če zdravilo dajete s hrano, preostanek nezaužite hrane takoj zavržite, da preprečite nenamerno zaužitje ostalim živalim ali ljudem v gospodinjstvu.
English: The selective inhibition of intestinal MTP also reduces intestinal fat absorption.
Slovenian: Selektivna inhibicija črevesnega MTP zniža tudi absorpcijo maščob v črevesju.
English: As an aid in the management of overweight and obesity in adult dogs.
Slovenian: Kot pomoč pri nadziranju prekomerne telesne mase in debelosti pri odraslih psih.
English: Do not use in cats due to the risk of development of hepatic lipidosis.
Slovenian: Ne uporabite zdravila pri mačkah zaradi tveganosti razvoja jetrne lipidoze.
English: Fertility studies have not been conducted in the target species.
Slovenian: Raziskav plodnosti niso izvajali na ciljnih živalski vrsti.
English: This is consistent with in vivo data generated in mice which shows that dirlotapide has selectivity for intestinal MTP.
Slovenian: To je skladno z in vivo pridobljenimi podatki na miših, kar kaže na selektivno delovanje dirlotapida na MTP.
English: The veterinarian will examine your dog at the beginning of treatment and recommend a starting dose.
Slovenian: Ob začetku zdravljenja bo veterinar pregledal psa in svetoval začetni odmerek zdravila.
English: Dirlotapide exhibited rapid oral absorption with mean Cmax values in the range of 8.5- 115 ng/ml, at 0.5 to 4 hours post-treatment (mean Tmax: 1.0 to 2.1 hours).
Slovenian: Dirlotapid se po peroralni uporabi hitro absorbira, povprečna Cmax je od 8,5 do 115 ng/ml v času 0,5 do 4 ure po dajanju (povprečen čas do maksimalnekoncentracije (tmax): 1,0 do 2,1 ure).
English: The inhibition of intestinal and hepatic MTP reduces plasma cholesterol and triglyceride concentration.
Slovenian: Inhibicija črevesnega in jetrnega MTP zniža koncentracijo holesterola in trigliceridov v plazmi.
English: Overdose up to 10 times the maximum authorised dose of 1 mg/kg current bodyweight may produce vomiting or diarrhoea or increased ALT/AST (alanine aminotransferase/aspartate aminotransferase) levels.
Slovenian: Uporaba do 10-krat večjega odmerka od maksimalno dovoljenega (1 mg/kg trenutne telesne mase) lahko povzroči bruhanje, diarejo ali povečanje ALT/AST (alanin aminotransferaza/aspartat aminotransferaza) vrednosti.
English: Dose 1 = Starting dose = Initial BW x
Slovenian: odmerek 1 = Začetni odmerek = Začetna
English: The veterinary medicinal product can be administered with or without food.
Slovenian: Zdravilo se daje s hrano ali brez nje.
English: Some dogs may show one or more vomiting events, sometimes accompanied by signs of tiredness, disinterest in food or diarrhoea, which reoccur occasionally during the course of treatment.
Slovenian: Pri nekaterih psih se lahko pojavi bruhanje, ki ga spremljajo znaki utrujenosti, nezanimanja za hrano ali diareja, ki se lahko tekom zdravljenja večkrat ponovijo.
English: Following these initial 4 weeks of therapy, dose adjustments are made monthly according to effect as described in section 9.
Slovenian: Po preteku začetnih 4 tednov zdravljenja se odmerki zdravila prilagajajo mesečno glede na učinke, ki so opisani v poglavju 9.
English: Withdraw the veterinary medicinal product from the bottle using the supplied dosing device and administer the veterinary medicinal product once daily directly into the mouth or on a small amount of food.
Slovenian: Zdravilo za uporabo v veterinarski medicini potegnite iz stekleničke z dodano odmerno napravo in ga dajte psu direktno v gobec ali na manjšo količino hrane enkrat na dan.
English: After two weeks of therapy, the initial dose (number of ml administered) should be increased by 100% (doubled).
Slovenian: Po prvih dveh tednih zdravljenja se začetni odmerek zdravila (količina apliciranih ml) poveča za 100 % (podvoji).